Has Caryn Axtell-Kelly received payments from drug or device companies?

Yes. Drug and device makers reported $6,500 in general payments to Caryn Axtell-Kelly across 366 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Caryn Axtell-Kelly did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Caryn Axtell-Kelly come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Caryn Axtell-Kelly

Medical · Chino, CANPI 1700815958

Payments from drug & device makers

$6,500in general payments, 2019–2025

Across 366 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
Medtronic$1K
Forte Bio-pharma LLC$720
Virtus Pharmaceuticals LLC$345
Collegium Pharmaceutical, Inc.$308
plus $2K from 24 others

What the payments were for

Travel & lodging$2714%
Food & beverage$6,17295%
Education$561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	58	$1,190
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	109	$1,072
Medtronic	19	$1,069
Forte Bio-pharma LLC	46	$720
Virtus Pharmaceuticals LLC	17	$345
Collegium Pharmaceutical, Inc.	19	$308
Scilex Pharmaceuticals Inc.	14	$280
Boston Scientific	9	$171
Pfizer	10	$170
Protega Pharmaceutials Inc	8	$157
Redhill Biopharma Inc.	8	$142
Arbor Pharmaceuticals, Inc.	5	$100
Nalu Medical, Inc.	5	$89
Hikma Pharmaceuticals USA	5	$83
Biohaven Pharmaceutical Holding Company Ltd.	4	$75
MML US, Inc.	4	$63
GRT US Holding, Inc.	2	$50
Abbott	2	$48
Merz Pharmaceuticals, LLC	2	$47
Biodelivery Sciences International, Inc.	3	$44
Painteq LLC	2	$38
Spinal Simplicity, LLC	2	$37
Almatica Pharma LLC	2	$32
Electronic Waveform Lab, Inc.	3	$32
Biohaven Pharmaceuticals, Inc.	2	$31
Azurity Pharmaceuticals, Inc.	2	$31
Tonix Medicines, Inc.	1	$23
Lundbeck LLC	1	$21
Curonix LLC	1	$17
Axsome Therapeutics, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,500 in reported general payments places this provider in the 90th percentile of 2,087 medical providers in California.

See all medical providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	438	$249,123
RelistorMethylnaltrexone Bromide	23	$51,786
Nurtec OdtRimegepant Sulfate	31	$43,875
BelbucaBuprenorphine Hcl	57	$40,512
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	1,215	$27,885
MovantikNaloxegol Oxalate	61	$24,524
Nucynta ErTapentadol Hcl	41	$21,634
Buprenorphine	85	$19,490
OxycontinOxycodone Hcl	42	$13,275
ZtlidoLidocaine	18	$12,936
QuliptaAtogepant	12	$12,322
Lidocaine	111	$12,144
NucyntaTapentadol Hcl	16	$11,470
Xtampza ErOxycodone Myristate	27	$10,238
Oxycodone Hcl	476	$9,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er, Nucynta, Xtampza Er	$308	$83,855141 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor	$1,072	$51,78623 claims
PfizerNurtec Odt	$170	$43,87531 claims
Redhill Biopharma Inc.Movantik	$142	$24,52461 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate	$83	$20,863152 claims
Scilex Pharmaceuticals Inc.Ztlido	$280	$12,93618 claims
AbbVieQulipta	$1,190	$12,32212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 medical providers in California.

Other medical in Chino

Nicola LowreyOrange$655K
Justin LoveLoma Linda$553K
David DoriguzziLancaster$514K
Alison GracomIrvine$467K
Jeffrey BonnaudLos Angeles$314K
Ana TorresLaguna Beach$229K
Heather ParlettRedlands$168K
Deirdre MoxleyFullerton$149K
Tri leGardena$127K
Linda RankLadera Ranch$105K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →